Radiation protection by deferiprone in animal models.
The effectiveness of deferiprone (L1) in removing depleted uranium (DU) and protecting animals from radiation exposure was examined. Rats that had received 2 mg/kg DU via intramuscular injection were orally administered 100, 200 or 400 mg/kg L1 for 3 days. In all of the groups, significant increases in urinary DU excretion and decreases in DU concentration in the injected muscle were observed, indicating that L1 combined with DU and DU was excreted in the urine. No significant increase in the amount of DU in the excreta or decrease in DU concentration in organs other than the muscles was found. As a preliminary test, the effectiveness of L1 in reducing radiation damage was examined in mice injected with 400 mg/kg L1 and rats administered orally with 200 and 400 mg/kg L1 before and just after x-ray exposure. The results were inconclusive.
Fukuda
Satoshi
S
Research Center for Radiation Emergency Medicine, National Institute of Radiological Sciences, Chiba, Japan. s_fukuda@nirs.go.jp
Ikeda
Mizuyo
M
Anzai
Kazunori
K
Suzuki
Masao
M
Katoh
Akira
A
Kontoghiorghes
George J
GJ
D000284:Administration, Oral; D000818:Animals; D002614:Chelating Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015913:Chelation Therapy; D000077543:Deferiprone; D004353:Drug Evaluation, Preclinical; D005243:Feces / Q000737:chemistry; D005269:Femur / Q000737:chemistry; D007668:Kidney / Q000737:chemistry; D007677:Kidney Function Tests; D008099:Liver / Q000737:chemistry; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D018482:Muscle, Skeletal / Q000737:chemistry; D011728:Pyridones / Q000008:administration & dosage / Q000627:therapeutic use*; D011833:Radiation Injuries, Experimental / Q000517:prevention & control*; D011837:Radiation-Protective Agents / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D014018:Tissue Distribution; D014501:Uranium / Q000032:analysis / Q000493:pharmacokinetics / Q000633:toxicity / Q000652:urine; D014502:Uranyl Nitrate / Q000008:administration & dosage / Q000493:pharmacokinetics; D014965:X-Rays / Q000009:adverse effects
D002614:Chelating Agents; D011728:Pyridones; D011837:Radiation-Protective Agents; D014502:Uranyl Nitrate; D000077543:Deferiprone; D014501:Uranium